Article

Autologous Hematopoietic Stem Cell Transplantation for Patients With Multiple Myeloma

Teresa Miceli

Kathryn E. Lilleby

Kimberly A. Noonan

Sandra Kurtin

Beth Faiman

Patricia Mangan

hematopoietic stem cell transplantation, stem cell transplantation, multiple myeloma, community health/home care, patient care
CJON 2013, 17(6), 13-24. DOI: 10.1188/13.CJON.S2.13-24

Autologous hematopoietic stem cell transplantation (AHSCT) is approved for the treatment of select solid tumors, autoimmune disorders, and most hematologic malignancies. Multiple myeloma (MM) is the most common indication for AHSCT. Despite improvement in response and survival rates in the era of novel agents, AHSCT remains an important treatment option for patients with MM who are eligible. Clinical management of patients with MM requires a multidisciplinary approach that incorporates healthcare professionals in a number of clinical settings as well as caregivers and the patient. Patients about to undergo AHSCT are generally referred to tertiary care centers that specialize in ASCT. Pre- and post-transplantation treatments and long-term follow-up often are managed by a community-based referring oncologist in collaboration with the transplantation team. Oncology nurses play an integral role in the care of patients with MM in each clinical setting. This article aims to provide non-transplantation oncology nurses with guidelines for education, clinical management, and support of patients with MM undergoing AHSCT with a primary focus on the pre- and post-transplantation period.

Jump to a section

    References

    Amgen Inc. (2013). Neupogen® (filgrastim) [Package insert]. Retrieved from http://pi.amgen.com/united_states/neupogen/neupogen_pi_hcp_english.pdf
    Antin, J., & Yolin Raley, D. (2009). Infectious disease, stem cell sources. In J. Antin & D. Yolin Raley (Eds.), Manual of stem cell and bone marrow transplantation (pp. 100-120). Cambridge, MA: Cambridge University Press.
    Attal, M. (1996). A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. New England Journal of Medicine, 335, 91-97. doi:10.1056/NEJM199607113350204
    Attal, M., Lauwers-Cances, V., Marit, G., Caillot, D., Moreau, P., Facon, T., … Harousseau, J. L. (2012). Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. New England Journal of Medicine, 366, 1782-1791. doi:10.1056/NEJMoa1114138
    Bensinger, W. I. (2009). Role of autologous and allogeneic stem cell transplantation in myeloma. Leukemia, 23, 442-448. doi:10.1038/leu.2008.396
    Bertolotti, P., Bilotti, E., Colson, K., Curran, K., Doss, D., Faiman, B., … Westphal, J. (2008). Management of side effects of novel therapies for multiple myeloma: Consensus statements developed by the International Myeloma Foundation's Nurse Leadership Board. Clinical Journal of Oncology Nursing, 12(3, Suppl.), 9-12. doi:10.1188/08.CJON.S1.9-12
    Bevans, M. (2009). Advances in stem cell transplantation. Seminars in Oncology Nursing, 25, 120-128. doi: 10.1016/j.soncn.2009.03.006
    Bilotti, E., Faiman, B. M., Richards, T. A., Tariman, J. D. Miceli, T. S., Rome, S. I., & the International Myeloma Foundation Nurse Leadership Board. (2011). Survivorship care guidelines for patients living with multiple myeloma: Consensus statements of the International Myeloma Foundation Nurse Leadership Board. Clinical Journal of Oncology Nursing, 15(Suppl., 1), 5-8. doi:10.1188/11.S1.CJON.5-8
    Bilotti, E., Gleason, C. L., & McNeill, A. (2011). Routine health maintenance in patients living with multiple myeloma: Survivorship care plan of the International Myeloma Foundation Nurse Leadership Board. Clinical Journal of Oncology Nursing, 15(Suppl., 1), 25-40. doi:10.1188/11.S1.CJON.25-40
    Blood and Marrow Transplant Information Network. (2013). Transplant center search form. Retrieved from http://www.bmtinfonet.org/centersearch?tid=613&treatment=All&field_addr_state_value_many_to_one=All&field_tc_unit_value=All
    Bristol-Myers Squibb. (2005). Cytoxan® (cyclophosphamide tablets) [Package insert]. Retrieved from http://packageinserts.bms.com/pi/pi_cytoxan.pdf
    Buschell, P. C., & Kapustay, P. M. (Eds.). (2009). Stem cell transplantation. A clinical textbook. Pittsburgh, PA: Oncology Nursing Society.
    Cavallo, F., Bringhen, S., Milone, G., Ben-Yehuda, D., Nagler, A., Calabrese, E., & Palumbo, A. (2011). Stem cell mobilization in patients with newly diagnosed multiple myeloma after lenalidomide induction therapy. Leukemia, 25, 1627-1631. doi:10.1038/leu.2011.131
    Cavo, M., Rajkumar, S. V., Palumbo, A., Moreau, P., Orlowski, R., Bladé, J., … International Myeloma Working Group. (2011). International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. Blood, 117, 6063-6073. doi:10.1182/blood-2011-02-297325
    Celgene Corporation. (2013a). Pomalyst® (pomalidomide) [Prescribing information]. Retrieved from http://www.pomalyst.com/docs/prescribing_information.pdf
    Celgene Corporation. (2013b). Revlimid® (lenalidomide) [Prescribing information]. Retrieved from http://www.revlimid.com/pdf/MCL_PI.pdf
    Celgene Corporation. (2013c). Thalomid® (thalidomide) [Prescribing information]. Retrieved from http://www.thalomid.com/pdf/Thalomid_PI.pdf
    Center for International Blood and Marrow Transplantation. (2013). Participating transplant centers. Retrieved from http://www.cibmtr.org/about/WhoWeAre/Centers/Pages/index.aspx
    Centers for Disease Control and Prevention. (2012). Respiratory syncytial virus infection. Retrieved from http://www.cdc.gov/rsv
    Chao, N. J., Tierney, D. K., Bloom, J. R., Long, G. D., Barr, T. A., Stallbaum, B. A., … Blume, K. G. (1992). Dynamic assessment of quality of life after autologous bone marrow transplantation. Blood, 80, 825-830.
    Cooke, L., Gemmill, R., Kravits, K., & Grant, M. (2009). Psychological issues of stem cell transplant. Seminars in Oncology Nursing, 25, 139-150.
    Cordonnier, C., Labopin, M., Chesnel, V., Ribaud, P., Cámara Rde, L., Martino, R., … Ljungman, P. (2010). Immune response to the 23-valent polysaccharide pneumococcal vaccine after the 7-valent conjugate vaccine in allogeneic stem cell transplant recipients: Results from the EBMT IDWOPO1 trial. Vaccine, 28, 2730-2734. doi:10.1016/j.vaccine.2010.01.025
    DiPersio, J. F., Stadtmauer, E. A., Nademanee, A., Micallef, I. N., Stiff, P. J., Kaufman, J. L., … Calandra, G. (2009). Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood, 113, 5720-5726.
    DiPersio, J. F., Uy, G. L., Yasothan, U., & Kirkpatrick, P. (2009). Plerixafor. Nature Reviews. Drug Discovery, 8, 105-107.
    Durie, B. G., Harousseau, J. L., Miguel, J. S., Bladé, J., Barlogie, B., Anderson, K., … Rajkumar, S. V. (2006). International uniform response criteria for multiple myeloma. Leukemia, 20, 1467-1473. doi:10.1038/sj.leu.2404284
    Eaton, L. E., & Tipton, J. M. (2010). A guide to oncology symptom management. Pittsburgh, PA: Oncology Nursing Society.
    Faiman, B., Miceli, T., Noonan, K., & Lilleby, K. (2013). Clinical updates in blood and marrow transplantation in multiple myeloma. Clinical Journal of Oncology Nursing, 17(Suppl., 2), 33-41.
    Faiman, B. M., Mangan, P., Spong, J., & Tariman, J. D. (2011). Renal complications in multiple myeloma and related disorders: Survivorship care plan of the International Myeloma Foundation Nurse Leadership Board. Clinical Journal of Oncology Nursing, 15(Suppl., 1), 66-76. doi:10.1188/11.CJON.S1.66-76
    Genzyme: A Sanofi Company. (2010). Mozobil® (plerixafor injection) [Prescribing information]. Retrieved from http://www.mozobil.com/document/Package_Insert.pdf
    Gertz, M. A., Kumar, S. K., Lacy, M. Q., Dispenzieri, A., Hayman, S. R., Buadi, F. K., … Litzow, M. R. (2009). Comparison of high-dose CY and growth factor with growth factor alone for mobilization of stem cells for transplantation in patients with multiple myeloma. Bone Marrow Transplant, 43, 619-625.
    GlaxoSmithKline. (2008). Alkeran® (melphalan hydrochloride) [Prescribing information]. Retrieved from http://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=13952
    Giralt, S., Stadtmauer, E. A., Harousseau, J. L., Palumbo, A., Bensinger, W., Comenzo, R. L., … Durie, B. G. (2009). International Myeloma Working Group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100). Leukemia, 23, 1904-1912. doi:10.1038/leu.2009.127
    Kapustay, P. M., & Buchsel, P. C. (2009). Process, complications, and management of peripheral stem cell transplantation. In P. C. Buchsel & P. M. Kapustay (Eds.), Stem cell transplantation: A clinical textbook (pp. 5.1-5.28). Pittsburgh, PA: Oncology Nursing Society.
    Kelley, C. H., McBride, L. H., Randolph, S. R., & Leum, E. (2000). Home care of peripheral blood stem cell transplantation recipients. In P. C. Buchsel & P. M. Kapustay (Eds.), Stem cell transplantation: A clinical textbook (pp. 131-136). Pittsburgh, PA: Oncology Nursing Society.
    Kroger, A., Sumaya, C., Pickering, L., & Atkinson, W. (2011). General recommendations on immunization: Recommendations of the Advisory Committee on Immunization Practices (ACIP). Morbidity and Mortality Weekly Report, 60(2), 1-64.
    Kumar, S. (2009). Stem cell transplantation for multiple myeloma. Current Opinions in Oncology, 21, 162-170. doi:10.1097/CCO.0b013e328324bc04
    Kurtin, S. A., Lilleby, K., & Spong, J. (2013). Caregivers of multiple myeloma survivors. Clinical Journal of Oncology Nursing, 17(Suppl., 2), 25-32.
    Kyle, R. A., Gertz, M. A., Witzig, T. E., Lust, J. A., Lacy, M. Q., Dispenzieri, A., … Greipp, P. R. (2003). Review of 1,027 patients with newly diagnosed multiple myeloma. Mayo Clinic Proceedings, 78, 21-33. doi:10.4065/78.1.21
    Kyle, R. A., & Rajkumar, S. V. (2009). Criteria for diagnosis, staging, risk stratification, and response assessment of multiple myeloma. Leukemia, 23, 3-9. doi:10.1038/leu.2008.291
    Lacy, M., Kumar, S., LaPlant, B., Laumann, K., Gertz, M., & Hayman, S. (2012). Pomalidomide plus low-dose dexamethasone (pom/dex) in relapsed myeloma: Long term follow up and factors predicting outcome in 345 patients [Abstract 201]. Blood, 120, 4176.
    Ljungman, P., Cordonnier, C., Englund, J., Machado, C. M., Storek, J., Small, T., … Centers for Disease Control and Prevention. (2009). Vaccination of hematopoietic cell transplant recipients. Bone Marrow Transplantation, 44, 521-526. doi:10.1038/bmt.2009.263
    Lokhorst, H., Einsele, H., Vesole, D., Bruno, B., Miguel, J., Pérez-Simon, J. A., … Bensinger, W. (2010). International Myeloma Working Group consensus statement regarding the current status of allogeneic stem-cell transplantation for multiple myeloma. Journal of Clinical Oncology, 28, 4521-4530.
    Lyons, D. K., Hull, J. G., Root, L. D., Kimtis, E., Shaal, A. D., Sterans, D. M., … Ahles, T. A. (2011). A pilot study of activity engagement in the first six months after stem cell transplantation. Oncology Nursing Forum, 38, 75-83. doi:10.1188/11.ONF.75-83
    Mangan, P. (2010). Patient assessment. In J. D. Tariman (Ed.), Multiple myeloma: A textbook for nurses (pp. 55-75). Pittsburgh, PA: Oncology Nursing Society.
    McCarthy, P. L., Owzar, K., Hofmeister, C. C., Hurd, D. D., Hassoun, H., Richardson, P. G., … Linker, C. (2012). Lenalidomide after stem-cell transplantation for multiple myeloma. New England Journal of Medicine, 366, 1770-1781. doi:10.1056/NEJMoa 1114083
    McQuellon, R. P., Russell, G. B., Rambo, T. D., Craven, B. L., Radford, J., Perry, J. J., … Hurd, D. D. (1998). Quality of life and psychological distress of bone marrow transplant recipients: The time trajectory to recovery over the first year. Bone Marrow Transplantation, 21, 477-486. doi:10.1038/sj.bmt.1701115
    Miceli, T. S., Colson, K., Faiman, B. M., Miller, K., & Tariman, J. D. (2011). Maintaining bone health in patients with multiple myeloma: Survivorship care plan of the International Myeloma Foundation Nurse Leadership Board. Clinical Journal of Oncology Nursing, 15(Suppl., 1), 9-23. doi:10.1188/11.S1.CJON.9-23
    Mikhael, J. R., Dingli, D., Roy, V., Reeder, C. B., Buadi, F. K., Hayman, S. R., … Lacy, M. Q. (2013). Management of newly diagnosed symptomatic multiple myeloma: Updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. Mayo Clinical Proceedings, 88, 360-376.
    Millennium: The Takeda Oncology Company. (2012). Velcade® (bortezomib) [Prescribing information]. Retrieved from http://www.velcade.com/Files/PDFs/VELCADE_PRESCRIBING_INFORMATION.pdf
    National Comprehensive Cancer Network. (2013). Clinical Practice Guidelines in Oncology: Multiple myeloma. Retrieved from http://www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf
    Novartis Pharmaceuticals. (2012a). Aredia® (pamidronate disodium) [Prescribing information]. Retrieved from http://www.pharma.us.novartis.com/product/pi/pdf/aredia.pdf
    Novartis Pharmaceuticals. (2012b). Zometa® (zoledronic acid) [Prescribing information]. Retrieved from http://www.pharma.us.novartis.com/product/pi/pdf/Zometa.pdf
    Onyx Pharmaceuticals. (2012). Kyprolis® (carfilzomib) [Prescribing information]. Retrieved from http://kyprolis.com/Content/pdf/PrescribingInformation.pdf
    Palumbo, A., & Anderson, K. (2011). Multiple myeloma. New England Journal of Medicine, 364, 1046-1060. doi:10.1056/NEJMra1011442
    Palumbo, A., Bladé, J., Boccadoro, M., Palladino, C., Davies, F., Dimopoulos, M., … San Miguel, J. (2012). How to manage neutropenia in multiple myeloma. Clinical Lymphoma Myeloma and Leukemia, 12, 5-11.
    Palumbo, A., Bringhen, S., Ludwig, H., Dimopoulos, M. A., Bladé, J., Mateos, M. V., … Sonneveld, P. (2011). Personalized therapy in multiple myeloma according to patient age and vulnerability: A report of the European Myeloma Network (EMN). Blood, 118, 4519-4529. doi:10.1182/blood-2011-06-358812
    Palumbo, A., & Cavallo, F. (2012). Have drug combinations supplanted stem cell transplantation in myeloma? Blood, 120, 4692-4698. doi:10.1182/blood-2012-05-423202
    Pasquini, M. C., & Wang, Z. (2011). Current use and outcome of hematopoietic stem cell transplantation: CIBMTR summary slides, 2011. Retrieved from http://www.cibmtr.org/ReferenceCenter/SlidesReports/SummarySlides/Pages/index.aspx
    Rajkumar, S. V., Jacobus, S., Callander, N. S., Fonseca, R., Vesole, D. H., Williams, M. E., … Greipp, P. R. (2010). Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: An open-label randomised controlled trial. Lancet Oncology, 11, 29-37. doi:10.1016/S1470-2045(09)70284-0
    Richards, T. A., Bertolotti, P. A., Doss, D., & McCullagh, E. J. (2011). Sexual dysfunction in multiple myeloma: Survivorship care plan of the International Myeloma Foundation Nurse Leadership Board. Clinical Journal of Oncology Nursing, 15(Suppl., 1), 53-65. doi:10.1188/11.CJON.S1.53-65
    Rodriguez, A. (2010a). Management and evaluation of patients receiving high dose therapy with stem cell transplant. In J. D. Tariman (Ed.), Multiple myeloma: A textbook for nurses (pp. 155-172). Pittsburgh, PA: Oncology Nursing Society.
    Rodriguez, A. (2010b). Treatment of newly diagnosed, transplant-eligible patients. In J. D. Tariman (Ed.), Multiple myeloma: A textbook for nurses (pp. 109-124). Pittsburgh, PA: Oncology Nursing Society.
    Rome, S. I., Jenkins, B. S., & Lilleby, K. E. (2011). Mobility and safety in the multiple myeloma survivor: Survivorship care plan of the International Myeloma Foundation Nurse Leadership Board. Clinical Journal of Oncology Nursing, 15(Suppl., 1), 41-52. doi:10.1188/11.S1.CJON.41-52
    Saleh, U. S., & Brockopp, D. Y. (2001). Quality of life one year following bone marrow transplantation: Psychometric evaluation of the quality of life in bone marrow transplant survivors tool. Oncology Nursing Forum, 28, 1457-1464.
    San Miguel, J. F., Schlag, R., Khuageva, N. K., Dimopoulos, M. A., Shpilberg, O., Kropff, M., … Richardson, P. G. (2008). Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. New England Journal of Medicine, 359, 906-917. doi:10.1056/NEJMoa0801479
    Schulmeister, L., Quiett, K., & Mayer, K. (2005). Quality of life, quality of care, and patient satisfaction: Perceptions of patients undergoing outpatient autologous stem cell transplantation. Oncology Nursing Forum, 32, 57-67. doi:10.1188/05.ONF.57-67
    Sipsas, N. V., & Kontoyiannis, D. P. (2008). Occupation, lifestyle, diet, and invasive fungal infections. Infection, 36, 515-525. doi:10.1007/s15010-008-8129-5
    Sonneveld, P., Asselbergs, E., Zweegman, S., Van Der Holt, B., Kersten, M., Vellenga, E., … Lokhorst, H. (2012). Carfilzomib combined with thalidomide and dexamethasone (ctd) is a highly effective induction and consolidation treatment in newly diagnosed patients with multiple myeloma (mm) who are transplant candidate [Abstract 333]. Blood, 120(21). Retrieved from http://myeloma.org/ArticlePage.action?articleId=3622 http://myeloma.org/ArticlePage.action?articleId=3622
    Sonneveld, P., Schmidt-Wolf, I., van der Holt, B., El Jarari, L., Bertsch, U., Salwender, H., … Goldschmidt, H. (2012). Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: Results of the randomized phase III HOVON-65/GMMG-HD4 trial. Journal of Clinical Oncology, 30, 2946-2955.
    Stadtmauer, E. A., Vogl, D. T., Luning Prak, E., Boyer, J., Aqui, N. A., Rapoport, A. P., … Sullivan, K. E. (2011). Transfer of influenza vaccine-primed costimulated autologous T cells after stem cell transplantation for multiple myeloma leads to reconstitution of influenza immunity: Results of randomized clinical trial. Blood, 117, 63-71. doi:10.1182/blood-2010-07-296822
    Tariman, J. (2010). Multiple myeloma: A textbook for nurses. Pittsburgh, PA: Oncology Nursing Society.
    Tichelli, A., Passweg, J., Wojcik, D., Rovo, A., Harousseau, J. L., Masszi, T., … Socie, G. (2008). Late cardiovascular events after allogeneic hematopoietic stem cell transplantation: A retrospective multicenter study of the Late Effects Working Party of the European Group for Blood and Marrow Transplantation. Haematologica, 93, 1203-1210. doi:10.3324/haematol.12949
    Tomblyn, M., Chiller, T., Einsele, H., Gress, R., Sepkowitz, K., Storek, J., … Boeckh, M. J. (2009). Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: A global perspective. Biology of Blood and Marrow Transplantation, 15, 1143-1238. doi:10.1016/j.bbmt.2009.06.019
    Versteeg, P. A., Slot, D. E., van der Velden, U., & van der Weijden, G. A. (2008). Effect of cannabis usage on the oral environment: A review. International Journal of Dental Hygiene, 6, 315-320.
    Williams, L. (2004). Post-transplant follow-up. In S. Ezzone (Ed.), Hematopoietic stem cell transplantation: A manual for nursing practice (pp. 207-220). Pittsburgh, PA: Oncology Nursing Society.